{"id":853623,"date":"2025-05-22T07:05:55","date_gmt":"2025-05-22T11:05:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-landmark-presentations-at-tides-usa-highlight-reproducibility-and-process-simplification-of-the-eco-synthesis-platform-for-manufacturing-sirna\/"},"modified":"2025-05-22T07:05:55","modified_gmt":"2025-05-22T11:05:55","slug":"codexis-landmark-presentations-at-tides-usa-highlight-reproducibility-and-process-simplification-of-the-eco-synthesis-platform-for-manufacturing-sirna","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-landmark-presentations-at-tides-usa-highlight-reproducibility-and-process-simplification-of-the-eco-synthesis-platform-for-manufacturing-sirna\/","title":{"rendered":"Codexis\u2019 Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA"},"content":{"rendered":"
\n

\u00a0Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases<\/em><\/p>\n

\n Management to host conference call today at 8 am Eastern Time to discuss data<\/em>\n <\/p>\n

REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis\u2019 presentations showcased its proprietary ECO Synthesis platform\u2019s ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demonstrating the potential to control stereochemistry. In addition, three presentations from contract development and manufacturing organizations (CDMOs) including Bachem, Nitto Avecia, and ST Pharm validated the transferability of Codexis\u2019 ligation processes to their in-house facilities.<\/p>\n

\u201cHaving been on the ground at TIDES this week, it is clear that siRNA technology has officially arrived,\u201d said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. \u201cWith a broader shift in favor of enzymatic manufacturing solutions and recent initiatives to onshore manufacturing, the rollout of our ECO Synthesis technology is quite timely. Our presentations at TIDES, including those from our three CDMO collaborators, validate the performance of our enzymatic approach and that the technology is now deployed at larger scale. We also showed how our technology can address some of the constraints associated with existing chemical synthesis methods, including intensive purification steps and lack of control over stereochemistry.\u201d<\/p>\n

Kevin Norrett, Chief Operating Officer of Codexis, added, \u201cSince the TIDES Europe meeting last fall, Codexis has emerged as the leader in enzymatic technology for manufacturing siRNA. Customers have gone from asking whether an enzymatic approach can work, to now asking how and when they can incorporate it into their drug development. Our job is to translate this momentum into genuine traction, including a GMP scale-up partnership by the end of the year.\u201d<\/p>\n

\n Codexis Showcases Improvements in Performance and Process Conditions of ECO Synthesis Platform <\/strong>\n <\/p>\n

During an oral Main Stage presentation, Codexis used inclisiran as an example to showcase how the use of immobilized enzymes in its ECO Synthesis platform delivers a consistent process with improved performance.<\/p>\n

Using sequential enzymatic synthesis, we:<\/p>\n